<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), novel disease-modifying treatments have been introduced and the SIE commissioned an update </plain></SENT>
<SENT sid="1" pm="."><plain>After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, graded according to the available evidence </plain></SENT>
<SENT sid="2" pm="."><plain>The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; <z:chebi fb="0" ids="49005">deferasirox</z:chebi> in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb &lt;10 g/dl and endogenous EPO &lt;500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients &lt;65 years without severe co morbidities </plain></SENT>
</text></document>